Summary & Overview
HCPCS J1652: Injection, fondaparinux sodium 0.5 mg
HCPCS Level II code J1652 denotes a 0.5 mg dose of fondaparinux sodium administered as an injection. Fondaparinux is an anticoagulant used in specific clinical indications where parenteral factor Xa inhibition is required; accurate coding for single-dose drug units ensures consistent billing and supports monitoring of utilization and costs at a national level. This code matters nationally because injectable anticoagulants are commonly used across hospital outpatient departments, physician offices, and ambulatory infusion centers, and small-unit codes like J1652 enable precise dosage-level billing.
Key payers covered in this publication include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical context and service settings, followed by benchmark considerations and policy-relevant notes on billing practice. The publication summarizes common modifiers and typical sites of service, outlines what data is available and what is not (where applicable), and points to common areas for payer policy alignment. Data not provided in the input—such as specific associated taxonomies, ICD-10 diagnoses, and related codes—is identified as unavailable.
Billing Code Overview
HCPCS Level II code J1652 represents an injection of fondaparinux sodium, 0.5 mg. This code is used to bill for the administered pharmaceutical product in a single-dose measure of 0.5 mg of fondaparinux sodium.
Service Type: Drug administration (subcutaneous or injectable anticoagulant)
Typical Site of Service: Outpatient clinic, physician office, or other ambulatory care settings where injectable anticoagulant therapy is provided
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult presenting for pharmacologic prophylaxis against venous thromboembolism (VTE) or treatment of acute deep vein thrombosis when fondaparinux dosing of 0.5 mg is appropriate (for example, as a pediatric or specialized low-dose clinical scenario). The workflow begins with a clinician order for J1652 (fondaparinux sodium, 0.5 mg) documented in the medical record with indication, weight-based dosing rationale, and informed consent when required. A licensed nurse or pharmacist prepares the subcutaneous injection using facility or outpatient pharmacy supply. Prior to administration, the provider verifies the patient identity, allergy history, recent coagulation studies if indicated, and concurrent anticoagulant or antiplatelet therapy. The injection is administered subcutaneously in the abdomen, thigh, or upper arm, with observation for immediate adverse reactions per facility protocol. Documentation includes the J1652 HCPCS code, lot number, expiration date, route (subcutaneous), site of administration, clinician or injector taxonomy, and any applicable modifier(s) reflecting circumstances such as service distinctness, drug wastage, or patient status. Billing follows payer-specific rules for drug administration, reporting the drug HCPCS plus any applicable administration CPT if required by the payor policy. Common clinical settings include inpatient wards, emergency departments, ambulatory infusion clinics, outpatient procedure areas, and specialty pediatric clinics when low-dose fondaparinux is indicated.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|